KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$2.0 billion.

  • Teva Pharmaceutical Industries' Income towards Parent Company rose 160.11% to $428.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.0 million, marking a year-over-year increase of 116.01%. This contributed to the annual value of -$2.0 billion for FY2024, which is 59.01% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Income towards Parent Company of -$2.0 billion as of FY2024, which was down 59.01% from -$1.2 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Income towards Parent Company high stood at -$519.0 million for FY2021, and its period low was -$5.3 billion during FY2020.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Income towards Parent Company value was -$2.0 billion (recorded in 2024), while the average stood at -$2.2 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Income towards Parent Company soared by 90.16% in 2021, and later tumbled by 538.54% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Income towards Parent Company stood at -$5.3 billion in 2020, then skyrocketed by 90.16% to -$519.0 million in 2021, then tumbled by 538.54% to -$3.3 billion in 2022, then skyrocketed by 62.67% to -$1.2 billion in 2023, then slumped by 59.01% to -$2.0 billion in 2024.